MidFirst Bank’s Alnylam Pharmaceuticals ALNY Stock Holding History

MidFirst Bank’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-541	Closed	-$16.3K	–	929
2025 Q4	$16.3K	Buy	+541	New	+$239K	﹤0.01%	552

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MidFirst Bank's ALNY Position: Q1 2026 in Review

MidFirst Bank sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 541 shares — an estimated $16.3K sold.

MidFirst Bank first reported a position in ALNY in Q4 2025 and held it in 1 quarter. The position peaked at $16.3K in Q4 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

MidFirst Bank reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
MidFirst Bank sold 541 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $16.3K.
MidFirst Bank first reported a position in Alnylam Pharmaceuticals in Q4 2025 and held it in 1 quarter.
MidFirst Bank's Alnylam Pharmaceuticals position peaked at $16.3K in Q4 2025.
791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on MidFirst Bank's 13F filing for Q1 2026, filed 15 May 2026.